ID
45989
Descripción
Principal Investigator: Himisha Beltran, Weill Cornell Medical College, New York, NY, USA MeSH: Adenocarcinoma,Prostatic Neoplasms,Neuroendocrine tumors https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000909 A subset of advanced prostate cancers can progress from an androgen receptor (AR)-driven state to AR independence, often associated with low or absent AR expression and extensive neuroendocrine differentiation. Once neuroendocrine prostate cancer (NEPC) develops, patients typically demonstrate an aggressive clinical course and poor overall survival. Early diagnosis is important but remains challenging as the clinical and pathologic features associate with AR independence and NEPC are poorly defined. We performed whole exome sequencing of 114 metastatic tumors from 81 patients (35 with morphologic features of NEPC). Serial or synchronous samples were included to characterize heterogeneity and the transition from adenocarcinoma to NEPC. Computational analysis of clonality and allele specific quantification were performed using CLONET. Quantitative mRNA assessment including AR signaling genes and DNA methylation were evaluated in the context of genomic changes.
Link
Palabras clave
Versiones (1)
- 8/4/24 8/4/24 - Madita Rudolph
Titular de derechos de autor
Himisha Beltran, Weill Cornell Medical College, New York, NY, USA
Subido en
8 de abril de 2024
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
dbGaP phs000909 Neuroendocrine Prostate Cancer (Trento/Cornell/Broad 2015)
This subject phenotype data table includes whether patients were included in the Nature Medicine study.
- StudyEvent: SEV1
- Eligibility Criteria
- This subject consent data table contains subject IDs, consent group information, and affection status for neuroendocrine prostate cancer (NEPC).
- This subject sample mapping data table includes a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. The data table also includes sample use.
- This sample attributes data table includes body site where sample was collected, analyte type, histological type, tumor status, and whether sample was included in the Nature Medicine study.
- This subject phenotype data table includes whether patients were included in the Nature Medicine study.
Similar models
This subject phenotype data table includes whether patients were included in the Nature Medicine study.
- StudyEvent: SEV1
- Eligibility Criteria
- This subject consent data table contains subject IDs, consent group information, and affection status for neuroendocrine prostate cancer (NEPC).
- This subject sample mapping data table includes a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. The data table also includes sample use.
- This sample attributes data table includes body site where sample was collected, analyte type, histological type, tumor status, and whether sample was included in the Nature Medicine study.
- This subject phenotype data table includes whether patients were included in the Nature Medicine study.
C2348585 (UMLS CUI [1,2])
C0002346 (UMLS CUI [1,2])
C0008976 (UMLS CUI [1,3])